Agenus Inc. (NASDAQ:AGEN)’s traded shares stood at 6.07 million during the last session, with the company’s beta value hitting 1.50. At the close of trading, the stock’s price was $1.89, to imply an increase of 5.59% or $0.1 in intraday trading. The AGEN share’s 52-week high remains $3.37, putting it -78.31% down since that peak but still an impressive 33.86% since price per share fell to its 52-week low of $1.25. The company has a valuation of $633.66M, with an average of 6.71 million shares in intraday trading volume over the past 10 days and average of 4.55 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Agenus Inc. (AGEN), translating to a mean rating of 1.70. Of 6 analyst(s) looking at the stock, 0 analyst(s) give AGEN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.21.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Agenus Inc. (NASDAQ:AGEN) trade information
After registering a 5.59% upside in the last session, Agenus Inc. (AGEN) has traded red over the past five days. The stock hit a weekly high of 1.9500 this Wednesday, 03/15/23, jumping 5.59% in its intraday price action. The 5-day price performance for the stock is 11.18%, and -14.48% over 30 days. With these gigs, the year-to-date price performance is -21.25%. Short interest in Agenus Inc. (NASDAQ:AGEN) saw shorts transact 22.14 million shares and set a 5.32 days time to cover.
Analysts on Wall Street suggest a consensus price target of $7.06, implying an increase of 73.23% to the stock’s current value. The extremes give us $5.00 and $8.30 for target low and target high price respectively. As such, AGEN has been trading -339.15% off suggested target high and -164.55% from its likely low.
Agenus Inc. (AGEN) estimates and forecasts
Looking at statistics comparing Agenus Inc. share performance against respective industry, we note that the company has underperformed competitors. Agenus Inc. (AGEN) shares are -24.10% down over the last 6 months, with its year-to-date growth rate lower than industry average at 5.13% against 9.90%. Revenue is forecast to grow 19.20% this quarter before falling -5.30% for the next one. The rating firms project that company’s revenue will shrink -69.60% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $21.9 million.
Agenus Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Agenus Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Agenus Inc. (NASDAQ:AGEN)’s Major holders
Agenus Inc. insiders hold 9.65% of total outstanding shares, with institutional holders owning 65.38% of the shares at 72.36% float percentage. In total, 65.38% institutions holds shares in the company, led by Deep Track Capital, LP. As of Sep 29, 2022, the company held over 26.32 million shares (or 8.64% of shares), all amounting to roughly $53.97 million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 22.85 million shares, or about 7.50% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $46.84 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Agenus Inc. (AGEN) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 16.75 million shares. This is just over 5.50% of the total shares, with a market valuation of $40.21 million. Data from the same date shows that the other fund manager holds a little less at 7.34 million, or 2.41% of the shares, all valued at about 15.06 million.